Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.
Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.
复制标题
程序性死亡 1 阻断抗体治疗难治性实体瘤的活性和免疫相关性
DOI：
10.7150/jca.21414
复制
发表时间：
2018
影响因子：
3.9
通讯作者：
Xia L
中科院分区：
文献类型：
--
作者：
Jiang C;Cai X;Zhang H;Xia X;Zhang B;Xia L
背景：阻断程序性死亡1(PD-1)是一种抑制性T淋巴细胞受体，在多种肿瘤中与免疫系统增强和肿瘤缓解有关。我们评估了接受抗PD-1抗体治疗的癌症患者的抗肿瘤活性和免疫相关性。患者和方法：12例晚期转移性肿瘤患者接受抗PD-1抗体治疗。在12周的治疗方案后评估疗效。每个周期前检测生化和免疫学指标。结果：12例患者中，3例部分缓解，6例病情稳定(客观有效率：3/12，25%；疾病控制率：9/12，75%)。在免疫治疗期间，稳定期患者外周血中CD3+T淋巴细胞比例保持稳定，CD3+CD4+T辅助细胞减少，CD3+CD8+T记忆细胞增加。此外，血清乳酸脱氢酶水平的升高似乎与肿瘤的进展有关。结论：一种抗PD-1抗体在约25%的各种实体瘤患者中产生了客观反应，表明它可以改善体内的免疫系统。
Background: Blockade of programmed death 1 (PD-1), an inhibitory T lymphocyte receptor, is associated with immune system enhancement and tumor remission in various tumors. We assessed the anti-tumor activity and immune correlates of cancer patients treated with an anti-PD-1 antibody. Patients and Methods: Twelve patients with advanced metastatic tumors were treated with anti-PD-1 antibody. Responses were assessed after a 12-week treatment regimen. Biochemical and immunological indexes were measured before each cycle. Results: Among the 12 patients, 3 patients showed partial response while 6 patients had stable disease (objective response rate: 3/12, 25%; disease control rate: 9/12, 75%). During immunotherapy, the proportion of circulating CD3+ T lymphocytes remained stable, with decreasing trends of CD3+CD4+ T helper cell and increase in CD3+CD8+ T memory cells, in patients with stable disease. Additionally, an increase in serum lactate dehydrogenase levels seemed to correlate with tumor progression. Conclusions: An anti-PD-1 antibody produced objective responses in approximately 25% patients with various solid tumors, demonstrating that it could improve the immune system in vivo.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
11.2
作者：
Blank, C;Brown, I;Gajewski, TF
通讯作者：
Gajewski, TF
影响因子：
30.5
作者：
Blackburn, Shawn D.;Shin, Haina;Haining, W. Nicholas;Zou, Tao;Workman, Creg J.;Polley, Antonio;Betts, Michael R.;Freeman, Gordon J.;Vignali, Dario A. A.;Wherry, E. John
通讯作者：
Wherry, E. John